Bimekizumab (IL-17A and IL-17F inhibitor) use in non-radiographic AxSpA resulted in rapid improvement of ASAS40 along with reduction in SPARCC MRI SI joint inflammation #Abs0544 @RheumNow #ACR22 https://t.co/pOCg0idGsR